[Home] [Reports] [Startups] [ONLINE STORE] [site map]

A Worldwide Business Report
from MedMarket Diligence
:

REPORT

Surgical Ablation Market Worldwide

Ablation Technologies Worldwide Market, 2009-2019

A worldwide report on the products, technologies, markets and opportunities in ablation

· 488 pages   · 123 Exhibits  · 76 Company Profiles     · June 2010     · Report #A145

 

Price:    $2,250 for print or PDF; add $200 to receive for both

Add $1,500 for site license or $2,500 for a global license(?) 

Order or via order form.

This exceptional report is a detailed market and technology assessment and forecast of the applications, products, technologies and opportunities in the global ablation market for treatment of soft tissues via energy-based modalities, including electrosurgery, radiosurgery, gamma knife, brachytherapy, cryosurgery, fluidjet therapy (hydrotherapy), microwave ablation, radiofrequency ablation, laser, thermal ablation, and ultrasonic ablation.

The report describes alternative energy-based technologies and the nature of their effect on soft tissue, the underlying basis of the technology, the requisite systems for their use (including capital equipment, devices and disposables), and their strengths and weaknesses for specific clinical applications. The report details current and anticipated target applications and assesses the current and forecast caseload for each energy-based therapeutic considering competition from any and all alternative energy-based or other therapeutics, with current and worldwide market forecasts (2009-2019) segmented by technology type and specific clinical segment. The report provides segmentation of the worldwide ablation market by both ablation technology and region/country: Americas (USA, Canada, Mexico, Brazil), Europe (Germany, United Kingdom, France, Italy, Spain, BeNeLux), Asia/Pacific (Japan, China, India, Australia) and Rest of World. The report details the current and emerging products, technologies and markets for each energy-based therapy. The report profiles 76 key companies in this industry detailing their current products, current market position and products under development.

Table of Contents

Executive Summary

 

Section 1:      DISEASE STATES TREATED WITH ENERGY-BASED ABLATIVE TECHNOLOGY

1.1        Overview of Ablation Technologies for the Treatment of Disease

1.1.1        Electrical

1.1.1.1         Enhancing Ablation Using Argon Gas

1.1.1.2         Irreversible Electroporation

1.1.2        Radiation

1.1.2.1         Image-guided radiotherapy (IGRT)

1.1.2.2         Image-modulated Radiotherapy (IMRT)

1.1.2.3         Tomotherapy

1.1.2.4         Increased Use of Hypofractionation, IGRT and IMRT

1.1.2.5         Hyperfractionation May Have its Benefits

1.1.2.6         Radiation and Concurrent Use of Chemotherapy

1.1.2.7         Brachytherapy

1.1.2.8         Stereotactic Radiosurgery and SBRT

1.1.2.9         FDA Tightening Approval Process for Radiation-emitting Devices

1.1.2.10       Nano-radiation Therapy

1.1.3        Light

1.1.3.1         Lasers and Their Effects on Tissue

1.1.4        Radiofrequency

1.1.4.1         Temperature Controlled

1.1.4.2         Fluid Cooled

1.1.4.3         Catheter Manipulation Systems

1.1.5        Ultrasound

1.1.6        Cryotherapy

1.1.7        Thermal

1.1.8        Microwave

1.1.9        Hydromechanical

1.1.10     Technologies Under Development

1.1.10.1       Induction Heating Cancer Therapy (IHCT) Using Magnetic Nanoparticles

1.1.11     Audiosurgery for Tumors

1.2        Disease States and Applicable Ablation Technologies

1.2.1        Cancer

1.2.1.1         Breast

1.2.1.1.1          Current and Emerging Treatment Trends

1.2.1.1.2          Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

1.2.1.2         Liver

1.2.1.2.1          Current and Emerging Treatment Trends

1.2.1.2.2          Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

1.2.1.3         Lung

1.2.1.3.1          Current and Emerging Treatment Trends

1.2.1.3.2          Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

1.2.1.4         Prostate Cancer

1.2.1.4.1          Gleason Grades and Scores

1.2.1.4.2          Prostate Cancer Staging

1.2.1.4.3          Current and Emerging Treatment Trends

1.2.1.4.4          Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

1.2.1.5         Kidney

1.2.1.5.1          Current and Emerging Treatment Trends

1.2.1.5.2          Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

1.2.2        Cardiovascular Disease

1.2.2.1         Angina Pectoris

1.2.2.1.1          Current and Emerging Treatment Trends

1.2.2.1.2          Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

1.2.2.2         Atrial Fibrillation and Atrial Flutter

1.2.2.2.1          Current and Emerging Treatment Trends

1.2.2.2.2          Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

1.2.2.3         Ventricular Arrhythmias

1.2.2.3.1          Current and Emerging Treatment Trends

1.2.2.3.2          Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

1.2.2.4         Wolf-Parkinson-White Disease

1.2.2.4.1          Current and Emerging Treatment Trends

1.2.2.4.2          Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

1.2.2.5         AVNRT (Atrioventricular nodal reentry tachycardia)

1.2.2.5.1          Current and Emerging Treatment Trends

1.2.2.5.2          Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

1.2.2.6         Critical Limb Ischemia

1.2.2.6.1          Current and Emerging Treatment Trends

1.2.2.6.2          Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

1.2.2.7         Critical Ischemic Stroke

1.2.2.7.1          Current and Emerging Treatment Trends

1.2.2.7.2          Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

1.2.2.8         Hypertension

1.2.2.8.1          Current and Emerging Treatment Trends

1.2.2.8.2          Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

1.2.2.9         Varicose Veins

1.2.2.9.1          Current and Emerging Treatment Trends

1.2.2.9.2          Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

1.2.3        Ophthalmology

1.2.3.1         Cataracts

1.2.3.1.1          Current and Emerging Treatment Trends

1.2.3.1.2          Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

1.2.3.2         Disorders of the Retina

1.2.3.2.1          Current and Emerging Treatment Trends

1.2.3.2.2          Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

1.2.3.3         Vision Correction

1.2.3.3.1          Current and Emerging Treatment Trends

1.2.3.3.2          Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

1.2.3.4         Central Retinal Vein Occlusion

1.2.3.4.1          Current and Emerging Treatment Trends

1.2.4        General Surgery

1.2.4.1         Barrett’s Esophagus

1.2.4.1.1          Current and Emerging Treatment Trends

1.2.4.1.2          Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

1.2.4.2         Fecal Incontinence

1.2.4.2.1          Current and Emerging Treatment Trends

1.2.4.2.2          Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

1.2.4.3         Gastroesophageal Reflux Disease (GERD)

1.2.4.3.1          Current and Emerging Treatment Trends

1.2.4.3.2          Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

1.2.4.4         Tonsillectomy

1.2.4.4.1          Current and Emerging Treatment Trends

1.2.4.4.2          Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

1.2.5        Gynecology

1.2.5.1         Menorrhagia

1.2.5.1.1          Current and Emerging Treatment Trends

1.2.5.1.2          Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

1.2.5.2         Fibroids

1.2.5.2.1          Current and Emerging Treatment Trends

1.2.5.2.2          Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

1.2.5.3         Cervical Dysplasia and Cancer

1.2.5.3.1          Current and Emerging Treatment Trends

1.2.5.3.2          Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

1.2.6        Pain Management

1.2.6.1         Current and Emerging Treatment Trends

1.2.6.2         Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

1.2.7        Urology

1.2.7.1         Kidney Stones

1.2.7.1.1          Current and Emerging Treatment Trends

1.2.7.1.2          Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

1.2.7.2         Benign Prostatic Hypertrophy (BPH)

1.2.7.2.1          Current and Emerging Treatment Trends

1.2.7.2.2          Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

1.2.8        Orthopedics

1.2.8.1         Joint Instability (Conducting Capsular Shrinkage)

1.2.8.1.1          Current and Emerging Treatment Trends

1.2.8.1.2          Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

1.2.8.2         Chondroplasty

1.2.8.2.1          Current and Emerging Treatment Trends

1.2.8.2.2          Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

1.2.8.3         Discogenic Back Pain

1.2.8.3.1          Current and Emerging Treatment Trends

1.2.8.3.2          Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

1.2.9        Aesthetic Treatments

1.2.9.1         Body Contouring

1.2.9.1.1          Current and Emerging Treatment Trends

1.2.9.1.2          Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

1.2.9.2         Laser Hair Removal

1.2.9.2.1          Current and Emerging Treatment Trends

1.2.9.2.2          Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

1.2.9.3         Laser Tattoo Removal

1.2.9.3.1          Current and Emerging Treatment Trends

1.2.9.3.2          Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

1.2.9.4         Port-wine Stains

1.2.9.4.1          Current and Emerging Treatment Trends

1.2.9.4.2          Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

1.2.9.5         Psoriasis

1.2.9.5.1          Current and Emerging Treatment Trends

1.2.9.5.2          Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

1.2.9.6         Scar Reduction and Removal

1.2.9.6.1          Current and Emerging Treatment Trends

1.2.9.6.2          Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

1.2.10     Other Treatments

1.2.10.1       Severe Asthma

1.2.10.1.1       Current and Emerging Treatment Trends

1.2.10.1.2       Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

1.2.10.2       Unresectable Liver Tumors

1.2.10.2.1       Current and Emerging Treatment Trends

1.2.10.2.2       Applicable Ablation Technologies: Rationale for Use and Effect on Tissues

Section 2:      Products and Technologies
Comprehensive product listing and selected recent developments discussed


2.1
        Electrical

2.2        Radiation

2.2.1        Brachytherapy

2.2.2        High-Dose-Rate (HDR) Brachytherapy

2.2.3        Pulsed-Dose-Rate (PDR) Brachytherapy

2.2.4        Permanent Seed Prostate Brachytherapy (LDR)

2.2.5        Stereotactic Radiosurgery (SRS) and Stereotactic Radiotherapy (SRT)

2.2.6        Stereotactic Body Radiation Therapy (SBRT)

2.2.7        Proton Beam Therapy

2.3        Light/Laser

2.4        Radiofrequency

2.4.1        RF Ablation for Atrial Fibrillation

2.4.2        RF Electrosurgical Devices

2.5        Ultrasound

2.6        Cryotherapy

2.7        Thermal

2.8        Microwave

2.9        Hydromechanical

 

Section 3:      Market Assessment

3.1        World Market Overview

3.2        Market Segmentation by Product Type

3.2.1        Electrical

3.2.2        Radiation

3.2.3        Light

3.2.4        Radiofrequency

3.2.5        Ultrasound

3.2.6        Cryotherapy

3.2.7        Thermal

3.2.8        Microwave

3.2.9        Hydromechanical

3.3        Market Trends

3.3.1        Market Drivers

3.3.1.1         Aging populations

3.3.1.2         Cardiac Arrhythmias

3.3.1.3         Cancer

3.3.1.4         Healthcare Economics

3.3.2        Market Restraints

3.3.2.1         Recession

3.3.2.2         US Healthcare Reforms

3.3.2.3         Procedure Time

3.3.2.4         Cost of Capital Expenditure

3.4        Leading Companies in Global Market

3.5        Major National Markets

3.5.1        Americas

3.5.1.1         U.S.A.

3.5.1.2         Canada

3.5.1.3         Mexico

3.5.1.4         Brazil

3.5.2        European Union

3.5.2.1         United Kingdom

3.5.2.2         Germany

3.5.2.3         France

3.5.2.4         Spain

3.5.2.5         Italy

3.5.2.6         BeNeLux

3.5.3        Asia/Pacific

3.5.3.1         Japan

3.5.3.2         China

3.5.3.3         India

3.5.3.4         Australia

3.5.4        Rest of World

Section 4:      Company Profiles

(Select companies profiled; note that not all companies covered in the report are profiled.)
 

4.1        Accuray

4.1.1        CyberKnife Robotic Radiosurgery System

4.1.2        CyberKnife VSI System

4.1.3        CyberKnife for Unresectable Renal Tumors

4.1.4        International Randomized Study to Compare CyberKnife Stereotactic Radiotherapy With Surgical Resection In Stage I Non-small Cell Lung Cancer (STARS)

4.1.5        CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry

4.1.6        CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Cancer

4.2        Alcon Laboratories

4.2.1        Infiniti Vision System

4.2.2        Constellation Vision System

4.2.3        Purepoint Laser

4.2.4        Allegretto Wave Eye-Q Excimer Laser System

4.2.5        Bid from Novartis to Acquire Alcon

4.3        American Medical Systems

4.3.1        TherMatrx Office Thermo Therapy

4.3.2        GreenLight Laser Therapy

4.4        AngioDynamics

4.4.1        StarBurst XL RFA device

4.4.2        The Habib 4X bipolar resection device

4.4.3        NanoKnife IRE System

4.4.4        VenaCure EVLT

4.4.5        A Prospective, Multi-Center, Clinical Trial Using Irreversible Electroporation (IRE) for the Treatment of Early-Stage Hepatocellular Carcinoma (HCC)

4.5        Ardian, Inc.

4.5.1        Symplicity I Trial

4.5.2        Symplicity HTN-2 Trial

4.6        ArthroCare Corporation

4.6.1        Coblation-Tonsillotomy vs Electrocautery-Tonsillectomy for the Treatment of Obstructive Sleep Apnea (OSA) in Children

4.7        Asthmatx, Inc.

4.7.1        Asthma Intervention Research 2 (AIR2) Trial

4.8        AtriCure

4.8.1        The AtriCure Synergy Bipolar System

4.8.2        Bipolar Radiofrequency Ablation of Permanent Atrial Fibrillation (ABLATE)

4.8.3        RESTORE SR IIB

4.9        ATS Medical

4.9.1        ATS CryoMaze

4.10     Bard Electrophysiology

4.10.1     MAGELLAN

4.11     Barrx Medical

4.11.1     Micro-Layer Ablation of Barrett's Metaplasia- A Two-Phase, Multi-Center Trial - Extension of Follow-up to 5 Years (AIM)

4.11.2     Endoscopic RF Ablation for Barrett’s Esophagus: Five-Year Durability Outcomes from a Prospective Multi-Center Trial

4.12     Bausch + Lomb

4.12.1     Stellaris Vision Enhancement System

4.12.2     Millennium Microsurgical System

4.13     Baylis Medical

4.13.1     TransDiscal System

4.14     Biosense Webster

4.14.1     Irrigated Tip Catheter product lines

4.14.2     NaviStar ThermoCool Catheter for the Treatment of AF—TX Clinical Trial

4.14.3     CLARITY Clinical Study

4.14.4     Study of a New Catheter Using Force Sensing Capabilities for the Treatment of AF and Ventricular Tachycardia (EZCF-125)

4.14.5     NaviStar ThermoCool Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF Clinical Trial

4.15     Biotronik

4.15.1     AlCath Flux/AlCath Flux Gold Ablation Catheters

4.16     Boston Scientific

4.16.1     VersaPulse PowerSuite 100 Watt Holmium laser

4.16.2     Prolieve Thermodilatation System

4.16.3     Blazer II X Temperature Ablation Catheter

4.16.4     RF 3000 Radiofrequency Ablation System

4.16.5     iLab Ultrasound Imaging System with Ultra ICE Catheter

4.16.6     Prolieve Post-Marketing Study Treatment of Benign Prostatic Hyperplasia (BPH)

4.16.7     A Prospective Randomized Study Comparing Radiofrequency Energy With Cryoenergy (CRYO-RF)

4.17     Bovie Medical

4.17.1     The Aaron line of electrosurgical products

4.17.2     The Bovie line of electrosurgery generators

4.17.3     MEG Endoscopic Instruments

4.18     BSD Medical

4.18.1     Phase III Clinical Trial of the BSD-2000 Hyperthermia System

4.18.2     Phase II MicroThermX® Microwave Ablation System (MTX-180)

4.18.3     BSD 500 Hyperthermia System

4.18.4     BSD-2000

4.19     Cardima

4.19.1     Cardima Surgical Ablation System

4.19.2     Cardima EP Ablation System

4.19.3     Cardima Revelation T-Flex Ablation device

4.20     CardioFocus

4.20.1     Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (CFEAS- AC) for the Treatment of Symptomatic Atrial Fibrillation

4.21     CardioGenesis

4.22     Celon AG

4.22.1     Surgery/Radiology

4.22.2     Phlebology

4.23     Chongqing Haifu (HIFU) Technology Co. Ltd.

4.24     Cook Group

4.24.1     LMA StoneBreaker Pneumatic Lithotripter

4.24.2     Odyssey 30 Holmium Laser System

4.24.3     The StoneBreaker Trial

4.25     ConMed

4.25.1     Beamer System CE600

4.26     Covidien

4.26.1     Electrosurgery

4.26.2     VNUS Medical Technologies

4.26.2.1       ClosureFAST System

4.26.2.2       LigaSure RF Ablation device

4.27     CryoMedix

4.28     CSA Medical

4.28.1     Study of CryoSpray Ablation to Determine Treatment Effect, Depth of Injury, and Side Effects in the Esophagus. (CSA Depth 3)

4.29     Cynosure

4.30     Dornier MedTech

4.30.1     Compact Delta II and Delta II UIMS

4.30.2     Dornier Lithotripter S II

4.30.3     Dornier Medilas D MultiBeam

4.30.4     Dornier Medilas H 20

4.31     EDAP TMS S.A.

4.31.1     Ablatherm HIFU

4.31.2     Sonolith i-move

4.31.3     ENLIGHT Clinical Trial

4.32     Elekta

4.32.1     Elekta Axesse

4.32.2     Elekta Infinity

4.32.3     Elekta Synergy S

4.32.4     Leksell Gamma Knife® Perfexion Stereotactic radiosurgery system

4.33     EndoPhotoniX

4.33.1     Solar & Atrilaze Atrial Fibrillation Trial (SAAF-T)

4.34     Endosense

4.34.1     TOCCATA Clinical Trial

4.34.2     EFFICAS I

4.35     Erbe Elektromedizin GmbH

4.36     Ethicon Endo-Surgery

4.37     Galil Medical

4.38     Gynesonics

4.39     Halt Medical

4.39.1     Laparoscopic Radiofrequency Ablation of Symptomatic Uterine Fibroids (Halt Lap RFA)

4.40     Hansen Medical

4.41     HealthTronics, Inc.

4.42     Hologic, Inc.

4.42.1     NovaSure Endometrial Ablation system

4.42.2     Digital mammography and breast biopsy

4.43     IBt-Bebig, SA

4.44     InSightec

4.44.1     ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Metastatic Bone Tumors for the Palliation of Pain

4.44.2     Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and Multiple Myeloma

4.45     Integra LifeSciences

4.46     Medtronic

4.46.1     Cardiac Rhythm Disease Management (CRDM)

4.46.2     Spinal and Biologics

4.46.3     CardioVascular

4.46.4     Neuromodulation

4.46.5     Diabetes

4.46.6     Surgical Technologies

4.46.7     AF Solutions Franchise

4.46.8     Arctic Front Cardiac CryoAblation Catheter

4.46.9     Cardiac CryoAblation System

4.46.10   The STOP AF Clinical Trial

4.46.11   The TTOP AF Clinical Trial

4.46.12   The CURE-AF/Perst Clinical Trial

4.47     Mederi Therapeutics

4.47.1     Secca Procedure for fecal incontinence

4.47.2     Stretta Procedure for GERD

4.48     MedWaves

4.49     Mirabilis Medica

4.50     Misonix

4.50.1     Sonablate 500

4.50.2     SonaStar Ultrasonic Surgical Aspirator

4.50.3     Bone Scalpel Ultrasonic Bone Cutter

4.51     nContact Surgical

4.51.1     Numeris Coagulation System with VisiTrax

4.51.2     Numeris-AF Tethered Coagulation System for Treatment of Longstanding Persistent Atrial Fibrillation (AF)

4.51.3     Safety and Efficacy Study of The Combined Ablation Procedure To Treat Longstanding Persistent Atrial Fibrillation (CAPstopsLSPAF)

4.51.4     Safety and Efficacy Study of the Combined Ablation Procedure to Treat Paroxysmal Atrial Fibrillation (CAP STOPS AF)

4.52     NeuWave Medical

4.52.1     Certus 140

4.53     Novian Health

4.53.1     Novilase

4.53.2     American Breast Laser Ablation Therapy Evaluation (ABLATE)

4.54     NuVue Therapeutics

4.55     Olympus Medical

4.55.1     UES-40 SurgMaster Electrosurgical Unit

4.55.2     SonoSurg Ultrasonic Surgical System

4.56     PhotoMedex

4.57     PhotoThera

4.58     RFA Medical

4.58.1     InCircle RF Ablation

4.59     Sanarus Technologies LLC

4.59.1     Cassi II Core Biopsy Device

4.59.2     ImarC Tissue Marker System

4.59.3     Visica 2 Treatment System

4.59.4     Z1072 Clinical Trial

4.60     SenoRx

4.60.1     Contura Multi-Lumen Balloon (MLB)

4.60.2     Multi-Site, Prospective, Non-Randomized Study of the Contura Multi-Lumen Balloon (MLB) Catheter to Deliver Accelerated Partial Breast Irradiation: Analysis of Dosimetry, Local Tumor Control, Cosmetic Outcome, and Toxicity

4.61     Siemens Healthcare

4.61.1     Siemens to put greater focus on healthcare businesses

4.61.2     Primatom System (IGRT)

4.61.3     Oncor

4.62     Smith & Nephew

4.62.1     Versajet Hydrosurgery System

4.62.2     Dyonics RF System

4.63     Solta Medical

4.63.1     Fraxel re:pair

4.64     Spectrasonics

4.65     St. Jude Medical

4.65.1     Atrial Fibrillation

4.65.2     CABANA Clinical Trial

4.65.3     IRASE AF Clinical Trial

4.65.4     Modified stepwise Ablation Guided by low dose Ibutilide Use in Chronic Atrial Fibrillation Trial (MAGIC-AF)

4.65.5     AFMAZE-CABG Clinical Trial

4.65.6     Clinical Evaluation of Therapy Cool Path Duo Cardiac Ablation System for the Treatment of Ischemic Ventricular Tachycardia (VT) (Ablate-VT)

4.66     Starion Instruments

4.67     Stereotaxis

4.67.1     Stereotaxis Magnetic Navigation System

4.68     Theragenics

4.69     TomoTherapy

4.69.1     Hi-Art Treatment System

4.70     Uptake Medical

4.70.1     Bronchoscopic Thermal Vapor Ablation (BTVA) for Lung Volume Reduction

4.71     Urologix

4.71.1     Targis System

4.72     US HIFU, LLC

4.72.1     Sonablate 500

4.72.2     Primary Prostate Cancer Clinical Trial

4.72.3     Recurrent HIFU Clinical Trial

4.73     Varian Medical Systems

4.73.1     Novalis Tx radiosurgery platform

4.73.2     RapidArc

4.73.3     Dynamic Targeting Image-Guided Radiation Therapy (IGRT)

4.73.4     SmartBeam IMRT

4.73.5     Dynamic Adaptive Radiotherapy (DART)

4.73.6     Acuity™ BrachyTherapy Suite™ integrated IGBT solution

4.73.7     Varian Proton Therapy System

4.74     Visualase

4.74.1     Magnetic Resonance Temperature Imaging & Imaging-Guided Laser Induced Thermal Therapy for Treatment of Metastatic Brain Tumors

4.75     Xoft

4.75.1     Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer (EXIBT)

4.75.2     Xoft Electronic Brachytherapy Clinical Protocol for the Primary Treatment of Non-Melanoma Skin Cancer

4.76     Zeltiq Aesthetics

4.76.1     Non-Invasive Reduction of Abdominal Fat (JUNO)

Section 5:      Key Clinical Trials

5.1        Electrical

5.1.1        AngioDynamics

5.1.1.1         A Prospective, Multi-Center, Clinical Trial Using Irreversible Electroporation (IRE) for the Treatment of Early-Stage Hepatocellular Carcinoma (HCC)

5.1.2        ArthroCare

5.1.2.1         Coblation-Tonsillotomy vs Electrocautery-Tonsillectomy for the Treatment of Obstructive Sleep Apnea (OSA) in Children

5.2        Radiation

5.2.1        Accuray

5.2.1.1         CyberKnife for Unresectable Renal Tumors

5.2.1.2         CyberKnife for Unresectable Renal Tumors

5.2.1.3         International Randomized Study to Compare CyberKnife Stereotactic Radiotherapy With Surgical Resection In Stage I Non-small Cell Lung Cancer (STARS)

5.2.1.4         CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry

5.2.1.5         CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Cancer

5.2.2        SenoRx

5.2.2.1         Multi-Site, Prospective, Non-Randomized Study of the Contura Multi-Lumen Balloon (MLB) Catheter to Deliver Accelerated Partial Breast Irradiation: Analysis of Dosimetry, Local Tumor Control, Cosmetic Outcome, and Toxicity

5.2.3        Xoft

5.2.3.1         Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer (EXIBT)

5.2.3.2         Xoft Electronic Brachytherapy Clinical Protocol for the Primary Treatment of Non-Melanoma Skin Cancer

5.3        Light

5.3.1        CardioFocus

5.3.1.1         Endoscopic Ablation System—Adaptive Contact (EAS-AC) for the Treatment of Symptomatic AF

5.3.2        EndoPhotoniX

5.3.2.1         Solar & Atrilaze Atrial Fibrillation Trial (SAAF-T)

5.3.3        Novian Health

5.3.3.1         American Breast Laser Ablation Therapy Evaluation (ABLATE)

5.3.4        Visualase

5.3.4.1         Magnetic Resonance Temperature Imaging & Imaging-Guided Laser Induced Thermal Therapy for Treatment of Metastatic Brain Tumors

5.4        Radiofrequency

5.4.1        Ardian, Inc.

5.4.1.1         Symplicity I Trial

5.4.1.2         Symplicity HTN-2 Trial

5.4.2        Asthmatx

5.4.2.1         Asthma Intervention Research 2 (AIR2) Trial

5.4.3        AtriCure

5.4.3.1         Bipolar Radiofrequency Ablation of Permanent Atrial Fibrillation (ABLATE)

5.4.3.2         RESTORE-SR IIB

5.4.4        Bard EP

5.4.4.1         MAGELLAN

5.4.5        Barrx Medical

5.4.5.1         Micro-Layer Ablation of Barrett's Metaplasia- A Two-Phase, Multi-Center Trial - Extension of Follow-up to 5 Years (AIM)

5.4.5.2         Endoscopic RF Ablation for Barrett’s Esophagus: Five-Year Durability Outcomes from a Prospective Multi-Center Trial

5.4.6        Biosense Webster

5.4.6.1         NaviStar ThermoCool Catheter for the Treatment of AF—TX Clinical Trial

5.4.6.2         CLARITY

5.4.6.3         Study of a New Catheter Using Force Sensing Capabilities for the Treatment of AF and Ventricular Tachycardia (EZCF-125)

5.4.6.4         NaviStar ThermoCool Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF Clinical Trial

5.4.7        BSD Medical

5.4.7.1         BSD-2000 RF Hyperthermia with Chemotherapy for Pancreatic Cancer

5.4.8        Endosense

5.4.8.1         EFFICAS I

5.4.8.2         TOCCATA Clinical Trial

5.4.9        Halt Medical

5.4.9.1         Laparoscopic Radiofrequency Ablation of Symptomatic Uterine Fibroids (Halt Lap RFA)

5.4.10     Medtronic

5.4.10.1       The CURE-AF/Perst Clinical Trial

5.4.10.2       The TTOP AF Clinical Trial

5.4.11     nContact Surgical

5.4.11.1       Numeris-AF Tethered Coagulation System for Treatment of Longstanding Persistent Atrial Fibrillation (AF)

5.4.11.2       Safety and Efficacy Study of The Combined Ablation Procedure To Treat Longstanding Persistent Atrial Fibrillation (CAPstopsLSPAF)

5.4.11.3       Safety and Efficacy Study of the Combined Ablation Procedure to Treat Paroxysmal Atrial Fibrillation (CAP STOPS AF)

5.4.12     St. Jude Medical

5.4.12.1       CABANA Clinical Trial

5.4.12.2       IRASE AF Clinical Trial

5.4.12.3       Modified stepwise Ablation Guided by low dose Ibutilide Use in Chronic Atrial Fibrillation Trial (MAGIC-AF)

5.4.12.4       Clinical Evaluation of Therapy Cool Path Duo Cardiac Ablation System for the Treatment of Ischemic Ventricular Tachycardia (VT) (Ablate-VT)

5.5        Ultrasound

5.5.1        EDAP TMS

5.5.1.1         Enlight Clinical Trial

5.5.2        InSightec

5.5.2.1         ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Metastatic Bone Tumors for the Palliation of Pain

5.5.3        St. Jude Medical

5.5.3.1         AFMAZE-CABG Clinical Trial

5.5.4        US HIFU

5.5.4.1         Clinical Study of the Sonablate® 500 to Treat Localized (T1c/T2a) Prostate Cancer (SetPace)

5.5.4.2         A Multicenter Clinical Study of the Sonablate 500 for the Treatment of Locally Recurrent Prostate Cancer With HIFU (STAR)

5.6        Cryotherapy

5.6.1        Boston Scientific

5.6.1.1         A Prospective Randomized Study Comparing Radiofrequency Energy with Cryoenergy (CRYO-RF)

5.6.2        CSA Medical

5.6.2.1         Study of CryoSpray Ablation to Determine Treatment Effect, Depth of Injury, and Side Effects in the Esophagus. (CSA Depth 3)

5.6.3        Medtronic

5.6.3.1         The STOP AF Clinical Trial

5.6.4        Sanarus Medical Technologies LLC

5.6.4.1         Z1072 Clinical Trial

5.6.5        Zeltiq Aesthetics

5.6.5.1         Non-Invasive Reduction of Abdominal Fat (JUNO)

5.7        Thermal

5.7.1        Ethicon

5.7.1.1         ThermaChoice III Under Local Sedation in the Office Setting

5.7.2        Uptake Medical

5.7.2.1         Bronchoscopic Thermal Vapor Ablation (BTVA) for Lung Volume Reduction (VAPOR)

5.8        Microwave

5.8.1        Boston Scientific

5.8.1.1         Prolieve Post-Marketing Study Treatment of Benign Prostatic Hyperplasia (BPH)

5.8.2        MedWaves

5.8.2.1         Microwave Ablation of Resectable Liver Tumors

5.9        Hydromechanical

5.9.1        Cook Medical

5.9.1.1         The StoneBreaker Trial

5.9.2        Smith & Nephew

5.9.2.1         Trial of Versajet Compared With Conventional Treatment in Acute and Chronic Wounds

Appendix I:  COMPANY DIRECTORY

 

Appendix II:  RELEVANT ORGANIZATIONS

 

Appendix III:  ABBREVIATIONS AND TERMS USED IN THIS REPORT

 

List of Exhibits

 

Exhibit ES-1:  Global Energy-based Ablation Devices Markets, 2009-2019

Exhibit ES-2:  Percent USD Shares of Global Market by Modality, Energy-based Ablation Devices, 2009

Exhibit ES-3:  Growth of the Global Energy-based Ablation Device Market, 2009-2019

Exhibit ES-4:  Global Incidence and Prevalence (where known) for Conditions Treated with Energy-Based Ablation Devices

Exhibit ES-5: Share of Energy-based Market by Clinical Market Segment, 2010

Exhibit ES-6:  Global Market Leaders, Energy-based Ablation Devices, 2009

Exhibit ES-7:  Leading Companies in Energy-based Ablation Device Market, 2010

 

Exhibit 1-1:  Global Number of Selected Surgical Procedures, Electrical Ablation, 2009

Exhibit 1-2:  Share of Energy-based Market by Clinical Market Segment, 2010

Exhibit 1-3:  World Age-Standardized Cancer Incidence per 100,000 Population (All Ages), by Cancer Type

Exhibit 1-4:  Global Incidence and Prevalence for Conditions Treated with Energy-Based Ablation Devices

Exhibit 1-5:  Staging of Prostate Cancer

Exhibit 1-6:  Treatment Options for Clinically Localized Prostate Cancer

Exhibit 1-7:  Estimated Total Cardiac Ablation Procedures, 2009 and 2019

Exhibit 1-8:  Actual and Estimated RF Ablation Procedures, 2009-2010: US, EU, Japan

 

Exhibit 2-1:  Energy-based Ablation Device Companies and Products

Exhibit 2-2:  Electrical Ablation Device Companies, Products & Applications

Exhibit 2-3:  Radiation Ablation Device Companies, Products & Applications

Exhibit 2-4:  States Not Covered by Medicare for CyberKnife Treatment of Prostate Cancer

Exhibit 2-5:  Light-based Ablation Device Companies, Products & Applications

Exhibit 2-6:  Radiofrequency-based Ablation Device Companies, Products & Applications

Exhibit 2-7:  Ultrasound-based Ablation Device Companies, Products & Applications

Exhibit 2-8:  Cryotherapy Ablation Device Companies, Products & Applications

Exhibit 2-9:  Thermal Ablation Device Companies, Products & Applications

Exhibit 2-10:  Microwave Ablation Device Companies, Products & Applications

Exhibit 2-11:  Hydromechanical Ablation Device Companies, Products & Applications

 

Exhibit 3-1:  Percent USD Shares of Global Market by Modality, Energy-based Ablation Devices, 2009

Exhibit 3-2:  2009 Energy-based Ablation Modalities Global Market Size & CAGR (2010-2019)

Exhibit 3-3:  Energy-Based Ablation Devices Global Market Sizes, 2009-2019 (USD millions)

Exhibit 3-4:  Global Energy-based Ablation Device Market, by Product Type, 2009-2019

Exhibit 3-5:  Global Electrical Ablation Market, 2009-2019

Exhibit 3-6:  Market Shares of Leading Competitors, Electrical, 2009

Exhibit 3-7:  Electrical Ablation Device Market, % per Region, 2009

Exhibit 3-8:  Americas Market for Electrical Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-9:  EU Market for Electrical Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-10:  Asia-Pacific Market for Electrical Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-11:  Rest of World Market for Electrical Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-12:  Global Radiation Ablation Market, 2009-2019

Exhibit 3-13:  Market Shares of Leading Competitors, Radiation Ablation Devices, 2009

Exhibit 3-14:  Radiation Ablation Device Market, % per Region, 2009

Exhibit 3-15:  Americas Market for Radiation Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-16:  EU Market for Radiation Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-17:  Asia-Pacific Market for Radiation Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-18:  Rest of World Market for Radiation Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-19:  Global Light-based Ablation Market, 2009-2019

Exhibit 3-20:  Light-based Ablation Device Market, % per Region, 2009

Exhibit 3-21:  Americas Market for Light-based Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-22:  EU Market for Light-based Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-23:  Asia-Pacific Market for Light-based Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-24:  Rest of World Market for Light-based Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-25:  Global Radiofrequency Ablation Market, 2009-2019

Exhibit 3-26:  Market Shares of Leading Competitors, Radiofrequency Ablation Devices, 2009

Exhibit 3-27:  Radiofrequency Ablation Device Market, % per Region, 2009

Exhibit 3-28:  Americas Market for Radiofrequency Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-29:  EU Market for Radiofrequency Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-30:  Asia-Pacific Market for Radiofrequency Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-31:  Rest of World Market for Radiofrequency Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-32:  Global Market for Ultrasound Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-33:  Market Shares of Leading Competitors, Ultrasound Ablation Devices, 2009

Exhibit 3-34:  Ultrasound Ablation Device Market, % per Region, 2009

Exhibit 3-35:  Americas Market for Ultrasound Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-36:  EU Market for Ultrasound Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-37:  Asia-Pacific Market for Ultrasound Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-38:  Rest of World Market for Ultrasound Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-39:  Global Market for Cryotherapy Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-40:  Market Shares of Leading Competitors, Cryotherapy Ablation Devices, 2009

Exhibit 3-41:  Americas Market for Cryotherapy Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-42:  EU Market for Cryotherapy Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-43:  Asia-Pacific Market for Cryotherapy Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-44:  Rest of World Market for Cryotherapy Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-45:  Global Market for Thermal Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-46:  Market Shares of Leading Competitors, Thermal Ablation Devices, 2009

Exhibit 3-47:  Thermal Ablation Device Market, % per Region, 2009

Exhibit 3-48:  Americas Market for Thermal Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-49:  EU Market for Thermal Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-50:  Asia-Pacific Market for Thermal Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-51:  Rest of World Market for Thermal Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-52:  Global Market for Microwave Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-53:  Market Shares of Leading Competitors, Microwave Ablation Devices, 2009

Exhibit 3-54:  Microwave Ablation Device Market, % per Region, 2009

Exhibit 3-55:  Americas Market for Microwave Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-56:  EU Market for Microwave Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-57:  Asia-Pacific Market for Microwave Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-58:  Rest of World Market for Microwave Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-59:  Global Market for Hydromechanical Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-60:  Market Shares of Leading Competitors, Hydromechanical Ablation Devices, 2009

Exhibit 3-61:  Americas Market for Hydromechanical Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-62:  EU Market for Hydromechanical Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-63:  Asia-Pacific Market for Hydromechanical Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-64:  Rest of World Market for Hydromechanical Ablation Devices, 2009-2019 (USD millions)

Exhibit 3-65:  Ablation Product Estimated Revenues in Cancer Applications, by Modality, 2010

Exhibit 3-66:  Leading Companies in the Global Energy-based Ablation Market, 2009

Exhibit 3-67:  Global Market Leaders, Energy-based Ablation Devices, 2009

Exhibit 3-68:  Energy-based Ablation Device Markets, USA, 2009-2019

Exhibit 3-69:  Energy-based Ablation Device Markets, Canada, 2009-2019

Exhibit 3-70:  Energy-based Ablation Device Markets, Mexico, 2009-2019

Exhibit 3-71:  Energy-based Ablation Device Markets, Brazil, 2009-2019

Exhibit 3-72:  Energy-based Ablation Device Markets, UK, 2009-2019

Exhibit 3-73:  Energy-based Ablation Device Markets, Germany, 2009-2019

Exhibit 3-74:  Energy-based Ablation Device Markets, France, 2009-2019

Exhibit 3-75:  Energy-based Ablation Device Markets, Spain, 2009-2019

Exhibit 3-76:  Energy-based Ablation Device Markets, Italy, 2009-2019

Exhibit 3-77:  Energy-based Ablation Device Markets, BeNeLux, 2009-2019

Exhibit 3-78:  Energy-based Ablation Device Markets, Japan, 2009-2019

Exhibit 3-79:  Energy-based Ablation Device Markets, China, 2009-2019

Exhibit 3-80:  Energy-based Ablation Device Markets, India, 2009-2019

Exhibit 3-81:  Energy-based Ablation Device Markets, Australia, 2009-2019

Exhibit 3-82:  Energy-based Ablation Device Markets, ROW, 2009-2019

 

Exhibit 4-1:  Accuray, Inc. Financial Results for Year Ending June 27, 2009

Exhibit 4-2:  AngioDynamics Consolidated Statement of Operations, July 2009

Exhibit 4-3:  ArthroCare Financial Results

Exhibit 4-4:  ATS Medical, Inc., Condensed Consolidated Statements of Operations

Exhibit 4-5:  Boston Scientific Corporation Financials, 2007-2009

Exhibit 4-6:  Covidien, Fiscal Years 2007-2009

Exhibit 4-7:  Elekta Income Statements, 2006-2009

Exhibit 4-8:  IBt-Bebig Financial Results, 2009

Exhibit 4-9:  Medtronic’s Company & Product Line Acquisitions, 2008-2010

Exhibit 4-10:  Medtronic Revenue by Operating Segment, 2008-2010

Exhibit 4-11:  Medtronic Annual Income Statements, 2006-2010

Exhibit 4-12:  SenoRx Financials, 2008-2009

Exhibit 4-13:  Summary of St. Jude Medical’s Products for Atrial Fibrillation

Exhibit 4-14:  Five-Year Summary Financial Data, St. Jude Medical

Exhibit 4-15:  Theragenics 2009 Annual Report: Net Income Statement

Exhibit 4-16:  Varian Medical Systems Financials, 2008-2009

 


Ablation Technologies Worldwide Market: Products, Technologies Markets, Companies and Opportunities, 2009-2019.  Report #A145.    Published June 2010
 

Price:    $2,250 for print or PDF; add $200 to receive for both

Add $1,500 for site license or $2,500 for a global license(?) 

Order online or via order form.

Methodology.
MedMarket Diligence Reports are produced through primary and secondary research. Data is gathered from published sources on products and technologies on the market and under development.  Clinicians and industry representatives are interviewed for their knowledge and insights on product development, market development, clinical practice and trends associated with the evolving use of technologies. Secondary data is used to corroborate and support assessments and projections.  Reports are written and researched by industry insiders, whose familiarity with the companies, industry dynamics and other marketplace specifics facilitate the research process and ensure high quality and thorough reports.



 Or contact: Patrick Driscoll, (949) 891-1753 or patrick <at> mediligence <dot> com.

Refund Policy:
MedMarket Diligence print publications may be returned within 30 calendar days of purchase and must be in re-saleable condition for a refund to be issued. No refunds will be provided for digital products such as PDFs; customers are therefore advised to carefully evaluate information (website samples, descriptions, and information otherwise provided by MedMarket Diligence) on publications prior to purchase.

Copyright © 2011 MedMarket Diligence, LLC. All rights reserved.

 

 

 

See free press releases

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Our clients


Or call
+1.949.891.1753

About Us

 

Read
advanced medical technologies
blog


Medtech Startups

 

 
Follow us on Twitter
Follow medmarket

MedMarket Diligence Reports Coverage

 

Medtech Startups
Online database of recent medtech startups

 

 

Contact Us